Michael Wittig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Wittig has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Andre Franke
Institute of Clinical Molecular Biology (IKMB), Christian‐Albrechts‐University of Kiel Kiel Germany
5 shared publications- Andre Franke
Institute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany
4 shared publications Christoph Gassner
Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Medical Center Schleswig-Holstein , Kiel 24105
3 shared publications- Tim Alexander Steiert
Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel & University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, 24118, Germany
3 shared publications - Antonio Julià
Rheumatology Research Group, Vall d’Hebron Research Institute, Barcelona, Spain
2 shared publications - Christoph Gassner
Institute of Translational Medicine, Private University in the Principality of Liechtenstein, Triesen, Liechtenstein
2 shared publications
Latest Publications
- Open Access
Genetics of Celiac Disease in Southern Brazil: High‐Resolution HLA Haplotypes and Non‐ HLA Polymorphisms
Celiac disease (CeD) is an autoimmune enteropathy triggered by gluten ingestion in genetically predisposed individuals, who frequently present HLA‐DQ2 or HLA‐DQ8 haplotypes. To examine the genetic architecture of CeD in the admixed South Brazilian population, we sequenced the HLA alleles to high resolution and genotyped 16 non‐HLA polymorphisms, previously identified through genome‐wide association studies of Europeans in 171 CeD diagnosed patients and 195 controls. Controls had no CeD diagnosis, no first‐degree affected relatives, and were negative for anti‐TTg autoantibodies. As expected, we observed a predominance of HLA ‐ DQA1*05:01:01~DQB1*02:01:01 (DQ2.5) and HLA ‐ DQA1*02:01:01~DQB1*02:02:01 (DQ2.2) haplotypes among patients (51.7% and 40.2%, respectively). The ancestral 8.1 haplotype of HLA Class I and II alleles presented the highest odds of developing CeD (OR = 6.54, pcorr = 0.000065). By contrast, HLA ‐ DQA1*01:02:01 , HLA ‐ DQB1*05:01:01 , HLA ‐ DRB1*08:02:01 and HLA ‐ DRB1*13:01:01 were more frequent among controls (OR < 0.4, pcorr < 0.01). In contrast to results obtained in populations of predominantly European origin, HLA‐DQ8 frequencies did not differ between patients and controls. Among non‐HLA loci, rs6691768*G (g.61326191G > A) in NFIA was associated with protection (OR = 0.32, pcorr = 0.039) and rs653178*C ( g.111569952C > T ) (OR = 1.49, pcorr = 0.042) in ATXN2 was associated with susceptibility. This is the first high‐resolution HLA genotyping study of CeD in Brazil, providing a comprehensive overview of genetic susceptibility in an admixed population and highlighting new potential modulatory variants beyond the classical HLA loci.
Open AccessGenetics of Celiac Disease in Southern Brazil: High‐Resolution HLA Haplotypes and Non‐ HLA Polymorphisms
Celiac disease (CeD) is an autoimmune enteropathy triggered by gluten ingestion in genetically predisposed individuals, who frequently present HLA‐DQ2 or HLA‐DQ8 haplotypes. To examine the genetic architecture of CeD in the admixed South Brazilian population, we sequenced the HLA alleles to high resolution and genotyped 16 non‐HLA polymorphisms, previously identified through genome‐wide association studies of Europeans in 171 CeD diagnosed patients and 195 controls. Controls had no CeD diagnosis, no first‐degree affected relatives, and were negative for anti‐TTg autoantibodies. As expected, we observed a predominance of HLA ‐ DQA1*05:01:01~DQB1*02:01:01 (DQ2.5) and HLA ‐ DQA1*02:01:01~DQB1*02:02:01 (DQ2.2) haplotypes among patients (51.7% and 40.2%, respectively). The ancestral 8.1 haplotype of HLA Class I and II alleles presented the highest odds of developing CeD (OR = 6.54, pcorr = 0.000065). By contrast, HLA ‐ DQA1*01:02:01 , HLA ‐ DQB1*05:01:01 , HLA ‐ DRB1*08:02:01 and HLA ‐ DRB1*13:01:01 were more frequent among controls (OR < 0.4, pcorr < 0.01). In contrast to results obtained in populations of predominantly European origin, HLA‐DQ8 frequencies did not differ between patients and controls. Among non‐HLA loci, rs6691768*G (g.61326191G > A) in NFIA was associated with protection (OR = 0.32, pcorr = 0.039) and rs653178*C ( g.111569952C > T ) (OR = 1.49, pcorr = 0.042) in ATXN2 was associated with susceptibility. This is the first high‐resolution HLA genotyping study of CeD in Brazil, providing a comprehensive overview of genetic susceptibility in an admixed population and highlighting new potential modulatory variants beyond the classical HLA loci.
- Open Access
- 4 May 2026
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
Calling for Diversity: Improving Transfusion Safety Through High-Throughput Blood Group Microarray Genotyping
Blood transfusions, conducted between donors compatible in their red blood cell (RBC) antigens, play a life-saving role in transfusion medicine. Genetic differences at blood group loci between ethnicities result in diversity and altered frequency of RBC antigens that need to be considered in blood transfusions. Consequently, comprehensive and accurate blood group antigen typing is especially relevant for interethnic blood transfusions and for minorities underrepresented in the donor population. Blood group microarray genotyping is a cost-efficient and scalable method for comprehensive blood group typing. Previously, however, microarray typing was challenging for the clinically important blood group systems Rh and MNS, as these feature highly paralogous genomic loci, which lead to mixed signals. Here, we present an approach for accurately typing blood group systems, including Rh and MNS variations. We benchmarked this approach in an ethnically diverse cohort. We tested its performance using gold-standard, diagnostic-grade matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) data from 1052 samples, including 334 Centre d’Etude du Polymorphisme Humain (CEPH)-diversity samples. Overall, we obtained a 99.95% benchmarking concordance and a 99.65% call rate. In summary, we provide a highly accurate and cost-efficient high-throughput genotyping method for comprehensive blood group analysis that is also suitable for ethnically diverse sample sets (https://github.com/ikmb/BloodTypingArray).
- 4 May 2026
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
Open AccessCalling for Diversity: Improving Transfusion Safety Through High-Throughput Blood Group Microarray Genotyping
Blood transfusions, conducted between donors compatible in their red blood cell (RBC) antigens, play a life-saving role in transfusion medicine. Genetic differences at blood group loci between ethnicities result in diversity and altered frequency of RBC antigens that need to be considered in blood transfusions. Consequently, comprehensive and accurate blood group antigen typing is especially relevant for interethnic blood transfusions and for minorities underrepresented in the donor population. Blood group microarray genotyping is a cost-efficient and scalable method for comprehensive blood group typing. Previously, however, microarray typing was challenging for the clinically important blood group systems Rh and MNS, as these feature highly paralogous genomic loci, which lead to mixed signals. Here, we present an approach for accurately typing blood group systems, including Rh and MNS variations. We benchmarked this approach in an ethnically diverse cohort. We tested its performance using gold-standard, diagnostic-grade matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) data from 1052 samples, including 334 Centre d’Etude du Polymorphisme Humain (CEPH)-diversity samples. Overall, we obtained a 99.95% benchmarking concordance and a 99.65% call rate. In summary, we provide a highly accurate and cost-efficient high-throughput genotyping method for comprehensive blood group analysis that is also suitable for ethnically diverse sample sets (https://github.com/ikmb/BloodTypingArray).
- Open Access
- 26 December 2024
- Published by Oxford University Press (OUP) in Bioinformatics Advances
- Vol. 5 (1) , vbaf210
bloodAGENT: a versatile tool for blood group typing and genomic variation analysis
Motivation: Accurate blood group allele determination is essential for both research and clinical applications. While next-generation sequencing and third-generation sequencing technologies provide a wealth of genomic data, secondary analysis pipelines often struggle with detecting variations in paralogous regions and maintaining haplotype integrity. Existing tools for blood group allele determination are frequently proprietary and lack the flexibility needed to address these challenges. To bridge this gap, we developed bloodAGENT, a versatile and open-source tool designed for analyzing genomic variation and resolving blood group alleles. Results: bloodAGENT achieves high concordance in blood group allele determination under typical conditions but reveals a strong dependence on data completeness. Simulations show that dropout rates are the primary determinant of concordance and ambiguities, with noticeable declines at dropout rates as low as 5%. While phasing breaks have a minor overall impact, their importance remains evident in specific scenarios. These results highlight bloodAGENT’s robustness and its potential for handling complex genomic analyses. Availability and implementation: https://github.com/ikmb/bloodAGENT.git.
- 26 December 2024
- Published by Oxford University Press (OUP) in Bioinformatics Advances
- Vol. 5 (1) , vbaf210
Open AccessbloodAGENT: a versatile tool for blood group typing and genomic variation analysis
Motivation: Accurate blood group allele determination is essential for both research and clinical applications. While next-generation sequencing and third-generation sequencing technologies provide a wealth of genomic data, secondary analysis pipelines often struggle with detecting variations in paralogous regions and maintaining haplotype integrity. Existing tools for blood group allele determination are frequently proprietary and lack the flexibility needed to address these challenges. To bridge this gap, we developed bloodAGENT, a versatile and open-source tool designed for analyzing genomic variation and resolving blood group alleles. Results: bloodAGENT achieves high concordance in blood group allele determination under typical conditions but reveals a strong dependence on data completeness. Simulations show that dropout rates are the primary determinant of concordance and ambiguities, with noticeable declines at dropout rates as low as 5%. While phasing breaks have a minor overall impact, their importance remains evident in specific scenarios. These results highlight bloodAGENT’s robustness and its potential for handling complex genomic analyses. Availability and implementation: https://github.com/ikmb/bloodAGENT.git.
- Open Access
- 23 April 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae146
Genome-wide meta-analysis of short-tandem repeats for Parkinson’s disease risk using genotype imputation
Idiopathic Parkinson’s disease is determined by a combination of genetic and environmental factors. Recently, the first genome-wide association study on short-tandem repeats in Parkinson’s disease reported on eight suggestive short-tandem repeat-based risk loci (α = 5.3 × 10−6), of which four were novel, i.e. they had not been implicated in Parkinson’s disease risk by genome-wide association analyses of single-nucleotide polymorphisms before. Here, we tested these eight candidate short-tandem repeats in a large, independent Parkinson’s disease case–control dataset (n = 4757). Furthermore, we combined the results from both studies by meta-analysis resulting in the largest Parkinson’s disease genome-wide association study of short-tandem repeats to date (n = 43 844). Lastly, we investigated whether leading short-tandem repeat risk variants exert functional effects on gene expression regulation based on methylation quantitative trait locus data in human ‘post-mortem’ brain (n = 142). None of the eight previously reported short-tandem repeats were significantly associated with Parkinson’s disease in our independent dataset after multiple testing correction (α = 6.25 × 10−3). However, we observed modest support for short-tandem repeats near CCAR2 and NCOR1 in the updated meta-analyses of all available data. While the genome-wide meta-analysis did not reveal additional study-wide significant (α = 6.3 × 10−7) short-tandem repeat signals, we identified seven novel suggestive Parkinson’s disease short-tandem repeat risk loci (α = 5.3 × 10−6). Of these, especially a short-tandem repeat near MEIOSIN showed consistent evidence for association across datasets. CCAR2, NCOR1 and one novel suggestive locus identified here (LINC01012) emerged from colocalization analyses showing evidence for a shared causal short-tandem repeat variant affecting both Parkinson’s disease risk and cis DNA methylation in brain. Larger studies, ideally using short-tandem repeats called from whole-sequencing data, are needed to more fully investigate their role in Parkinson’s disease.
- 23 April 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae146
Open AccessGenome-wide meta-analysis of short-tandem repeats for Parkinson’s disease risk using genotype imputation
Idiopathic Parkinson’s disease is determined by a combination of genetic and environmental factors. Recently, the first genome-wide association study on short-tandem repeats in Parkinson’s disease reported on eight suggestive short-tandem repeat-based risk loci (α = 5.3 × 10−6), of which four were novel, i.e. they had not been implicated in Parkinson’s disease risk by genome-wide association analyses of single-nucleotide polymorphisms before. Here, we tested these eight candidate short-tandem repeats in a large, independent Parkinson’s disease case–control dataset (n = 4757). Furthermore, we combined the results from both studies by meta-analysis resulting in the largest Parkinson’s disease genome-wide association study of short-tandem repeats to date (n = 43 844). Lastly, we investigated whether leading short-tandem repeat risk variants exert functional effects on gene expression regulation based on methylation quantitative trait locus data in human ‘post-mortem’ brain (n = 142). None of the eight previously reported short-tandem repeats were significantly associated with Parkinson’s disease in our independent dataset after multiple testing correction (α = 6.25 × 10−3). However, we observed modest support for short-tandem repeats near CCAR2 and NCOR1 in the updated meta-analyses of all available data. While the genome-wide meta-analysis did not reveal additional study-wide significant (α = 6.3 × 10−7) short-tandem repeat signals, we identified seven novel suggestive Parkinson’s disease short-tandem repeat risk loci (α = 5.3 × 10−6). Of these, especially a short-tandem repeat near MEIOSIN showed consistent evidence for association across datasets. CCAR2, NCOR1 and one novel suggestive locus identified here (LINC01012) emerged from colocalization analyses showing evidence for a shared causal short-tandem repeat variant affecting both Parkinson’s disease risk and cis DNA methylation in brain. Larger studies, ideally using short-tandem repeats called from whole-sequencing data, are needed to more fully investigate their role in Parkinson’s disease.
- Open Access
- 4 April 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (14) , 1391-1398
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL
Distinct diagnostic entities within BCR::ABL1-positive acute lymphoblastic leukemia (ALL) are currently defined by the International Consensus Classification of myeloid neoplasms and acute leukemias (ICC): “lymphoid only”, with BCR::ABL1 observed exclusively in lymphatic precursors, vs “multilineage”, where BCR::ABL1 is also present in other hematopoietic lineages. Here, we analyzed transcriptomes of 327 BCR::ABL1-positive patients with ALL (age, 2-84 years; median, 46 years) and identified 2 main gene expression clusters reproducible across 4 independent patient cohorts. Fluorescence in situ hybridization analysis of fluorescence-activated cell-sorted hematopoietic compartments showed distinct BCR::ABL1 involvement in myeloid cells for these clusters (n = 18/18 vs n = 3/16 patients; P < .001), indicating that a multilineage or lymphoid BCR::ABL1 subtype can be inferred from gene expression. Further subclusters grouped samples according to cooperating genomic events (multilineage: HBS1L deletion or monosomy 7; lymphoid: IKZF1-/- or CDKN2A/PAX5 deletions/hyperdiploidy). A novel HSB1L transcript was highly specific for BCR::ABL1 multilineage cases independent of HBS1L genomic aberrations. Treatment on current German Multicenter Study Group for Adult ALL (GMALL) protocols resulted in comparable disease-free survival (DFS) for multilineage vs lymphoid cluster patients (3-year DFS: 70% vs 61%; P = .530; n = 91). However, the IKZF1-/- enriched lymphoid subcluster was associated with inferior DFS, whereas hyperdiploid cases showed a superior outcome. Thus, gene expression clusters define underlying developmental trajectories and distinct patterns of cooperating events in BCR::ABL1-positive ALL with prognostic relevance.
- 4 April 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (14) , 1391-1398
Open AccessDevelopmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL
Distinct diagnostic entities within BCR::ABL1-positive acute lymphoblastic leukemia (ALL) are currently defined by the International Consensus Classification of myeloid neoplasms and acute leukemias (ICC): “lymphoid only”, with BCR::ABL1 observed exclusively in lymphatic precursors, vs “multilineage”, where BCR::ABL1 is also present in other hematopoietic lineages. Here, we analyzed transcriptomes of 327 BCR::ABL1-positive patients with ALL (age, 2-84 years; median, 46 years) and identified 2 main gene expression clusters reproducible across 4 independent patient cohorts. Fluorescence in situ hybridization analysis of fluorescence-activated cell-sorted hematopoietic compartments showed distinct BCR::ABL1 involvement in myeloid cells for these clusters (n = 18/18 vs n = 3/16 patients; P < .001), indicating that a multilineage or lymphoid BCR::ABL1 subtype can be inferred from gene expression. Further subclusters grouped samples according to cooperating genomic events (multilineage: HBS1L deletion or monosomy 7; lymphoid: IKZF1-/- or CDKN2A/PAX5 deletions/hyperdiploidy). A novel HSB1L transcript was highly specific for BCR::ABL1 multilineage cases independent of HBS1L genomic aberrations. Treatment on current German Multicenter Study Group for Adult ALL (GMALL) protocols resulted in comparable disease-free survival (DFS) for multilineage vs lymphoid cluster patients (3-year DFS: 70% vs 61%; P = .530; n = 91). However, the IKZF1-/- enriched lymphoid subcluster was associated with inferior DFS, whereas hyperdiploid cases showed a superior outcome. Thus, gene expression clusters define underlying developmental trajectories and distinct patterns of cooperating events in BCR::ABL1-positive ALL with prognostic relevance.
- Open Access
Calling for diversity: improving transfusion safety through high-throughput blood group microarray genotyping
Blood transfusions, conducted between donors compatible in their red blood cell (RBC) antigens, play a life-saving role in transfusion medicine. Genetic differences at blood group loci between ethnicities result in diversity and altered frequency of RBC antigens that need to be considered in blood transfusion. Consequently, comprehensive, and accurate blood group antigen typing is especially relevant for inter-ethnic blood transfusions and for minorities underrepresented in the donor population. Blood group microarray genotyping is a cost-efficient and scalable method for comprehensive blood group typing. Previously, however, microarray typing has been challenging for the clinically important blood group systems Rh and MNS, as these feature highly paralogous genomic loci leading to mixed signals. We here present an approach for accurately typing blood group systems, including Rh and MNS variations, that we benchmarked in an ethnically diverse cohort. We tested its performance using gold-standard, diagnostic-grade MALDI-TOF data from 1,052-samples, including 334 CEPH diversity samples and applied the approach to 4,999 samples of a COVID-19 genetics study. Overall, we obtained a 99.95% benchmarking concordance and 99.65% call rate. In summary, we provide a highly accurate and cost-efficient high-throughput genotyping method for comprehensive blood group analysis that is also suitable for ethnically diverse sample sets.
Open AccessCalling for diversity: improving transfusion safety through high-throughput blood group microarray genotyping
Blood transfusions, conducted between donors compatible in their red blood cell (RBC) antigens, play a life-saving role in transfusion medicine. Genetic differences at blood group loci between ethnicities result in diversity and altered frequency of RBC antigens that need to be considered in blood transfusion. Consequently, comprehensive, and accurate blood group antigen typing is especially relevant for inter-ethnic blood transfusions and for minorities underrepresented in the donor population. Blood group microarray genotyping is a cost-efficient and scalable method for comprehensive blood group typing. Previously, however, microarray typing has been challenging for the clinically important blood group systems Rh and MNS, as these feature highly paralogous genomic loci leading to mixed signals. We here present an approach for accurately typing blood group systems, including Rh and MNS variations, that we benchmarked in an ethnically diverse cohort. We tested its performance using gold-standard, diagnostic-grade MALDI-TOF data from 1,052-samples, including 334 CEPH diversity samples and applied the approach to 4,999 samples of a COVID-19 genetics study. Overall, we obtained a 99.95% benchmarking concordance and 99.65% call rate. In summary, we provide a highly accurate and cost-efficient high-throughput genotyping method for comprehensive blood group analysis that is also suitable for ethnically diverse sample sets.
- Open Access
- 15 March 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (6) , 878-892
Haplotype sequence collection of ABO blood group alleles by long-read sequencing reveals putative A1-diagnostic variants
In the era of blood group genomics, reference collections of complete and fully resolved blood group gene alleles have gained high importance. For most blood groups, however, such collections are currently lacking, as resolving full-length gene sequences as haplotypes (ie, separated maternal/paternal origin) remains exceedingly difficult with both Sanger and short-read next-generation sequencing. Using the latest third-generation long-read sequencing, we generated a collection of fully resolved sequences for all 6 main ABO allele groups: ABO∗A1/A2/B/O.01.01/O.01.02/O.02. We selected 77 samples from an ABO genotype data set (n = 25 200) of serologically typed Swiss blood donors. The entire ABO gene was amplified in 2 overlapping long-range polymerase chain reactions (covering ∼23.6 kb) and sequenced by long-read Oxford Nanopore sequencing. For quality validation, 2 samples per ABO group were resequenced using Illumina and Pacific Biosciences technology. All 154 full-length ABO sequences were resolved as haplotypes. We observed novel, distinct sequence patterns for each ABO group. Most genetic diversity was found between, not within, ABO groups. Phylogenetic tree and haplotype network analyses highlighted distinct clades of each ABO group. Strikingly, our data uncovered 4 genetic variants putatively specific for ABO∗A1, for which direct diagnostic targets are currently lacking. We validated A1-diagnostic potential using whole-genome data (n = 4872) of a multiethnic cohort. Overall, our sequencing strategy proved powerful for producing high-quality ABO haplotypes and holds promise for generating similar collections for other blood groups. The publicly available collection of 154 haplotypes will serve as a valuable resource for molecular analyses of ABO, as well as studies about the function and evolutionary history of ABO.
- 15 March 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (6) , 878-892
Open AccessHaplotype sequence collection of ABO blood group alleles by long-read sequencing reveals putative A1-diagnostic variants
In the era of blood group genomics, reference collections of complete and fully resolved blood group gene alleles have gained high importance. For most blood groups, however, such collections are currently lacking, as resolving full-length gene sequences as haplotypes (ie, separated maternal/paternal origin) remains exceedingly difficult with both Sanger and short-read next-generation sequencing. Using the latest third-generation long-read sequencing, we generated a collection of fully resolved sequences for all 6 main ABO allele groups: ABO∗A1/A2/B/O.01.01/O.01.02/O.02. We selected 77 samples from an ABO genotype data set (n = 25 200) of serologically typed Swiss blood donors. The entire ABO gene was amplified in 2 overlapping long-range polymerase chain reactions (covering ∼23.6 kb) and sequenced by long-read Oxford Nanopore sequencing. For quality validation, 2 samples per ABO group were resequenced using Illumina and Pacific Biosciences technology. All 154 full-length ABO sequences were resolved as haplotypes. We observed novel, distinct sequence patterns for each ABO group. Most genetic diversity was found between, not within, ABO groups. Phylogenetic tree and haplotype network analyses highlighted distinct clades of each ABO group. Strikingly, our data uncovered 4 genetic variants putatively specific for ABO∗A1, for which direct diagnostic targets are currently lacking. We validated A1-diagnostic potential using whole-genome data (n = 4872) of a multiethnic cohort. Overall, our sequencing strategy proved powerful for producing high-quality ABO haplotypes and holds promise for generating similar collections for other blood groups. The publicly available collection of 154 haplotypes will serve as a valuable resource for molecular analyses of ABO, as well as studies about the function and evolutionary history of ABO.
- Open Access
- 13 July 2022
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 4 (3) , lqac051
High-throughput method for the hybridisation-based targeted enrichment of long genomic fragments for PacBio third-generation sequencing
Hybridisation-based targeted enrichment is a widely used and well-established technique in high-throughput second-generation short-read sequencing. Despite the high potential to genetically resolve highly repetitive and variable genomic sequences by, for example PacBio third-generation sequencing, targeted enrichment for long fragments has not yet established the same high-throughput due to currently existing complex workflows and technological dependencies. We here describe a scalable targeted enrichment protocol for fragment sizes of >7 kb. For demonstration purposes we developed a custom blood group panel of challenging loci. Test results achieved > 65% on-target rate, good coverage (142.7×) and sufficient coverage evenness for both non-paralogous and paralogous targets, and sufficient non-duplicate read counts (83.5%) per sample for a highly multiplexed enrichment pool of 16 samples. We genotyped the blood groups of nine patients employing highly accurate phased assemblies at an allelic resolution that match reference blood group allele calls determined by SNP array and NGS genotyping. Seven Genome-in-a-Bottle reference samples achieved high recall (96%) and precision (99%) rates. Mendelian error rates were 0.04% and 0.13% for the included Ashkenazim and Han Chinese trios, respectively. In summary, we provide a protocol and first example for accurate targeted long-read sequencing that can be used in a high-throughput fashion.
- 13 July 2022
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 4 (3) , lqac051
Open AccessHigh-throughput method for the hybridisation-based targeted enrichment of long genomic fragments for PacBio third-generation sequencing
Hybridisation-based targeted enrichment is a widely used and well-established technique in high-throughput second-generation short-read sequencing. Despite the high potential to genetically resolve highly repetitive and variable genomic sequences by, for example PacBio third-generation sequencing, targeted enrichment for long fragments has not yet established the same high-throughput due to currently existing complex workflows and technological dependencies. We here describe a scalable targeted enrichment protocol for fragment sizes of >7 kb. For demonstration purposes we developed a custom blood group panel of challenging loci. Test results achieved > 65% on-target rate, good coverage (142.7×) and sufficient coverage evenness for both non-paralogous and paralogous targets, and sufficient non-duplicate read counts (83.5%) per sample for a highly multiplexed enrichment pool of 16 samples. We genotyped the blood groups of nine patients employing highly accurate phased assemblies at an allelic resolution that match reference blood group allele calls determined by SNP array and NGS genotyping. Seven Genome-in-a-Bottle reference samples achieved high recall (96%) and precision (99%) rates. Mendelian error rates were 0.04% and 0.13% for the included Ashkenazim and Han Chinese trios, respectively. In summary, we provide a protocol and first example for accurate targeted long-read sequencing that can be used in a high-throughput fashion.
- 15 March 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 204 (6) , 1571-1581
In Silico Guided Discovery of Novel Class I and II Trypanosoma cruzi Epitopes Recognized by T Cells from Chagas’ Disease Patients
T cell–mediated immune response plays a crucial role in controlling Trypanosoma cruzi infection and parasite burden, but it is also involved in the clinical onset and progression of chronic Chagas’ disease. Therefore, the study of T cells is central to the understanding of the immune response against the parasite and its implications for the infected organism. The complexity of the parasite–host interactions hampers the identification and characterization of T cell–activating epitopes. We approached this issue by combining in silico and in vitro methods to interrogate patients’ T cells specificity. Fifty T. cruzi peptides predicted to bind a broad range of class I and II HLA molecules were selected for in vitro screening against PBMC samples from a cohort of chronic Chagas’ disease patients, using IFN-γ secretion as a readout. Seven of these peptides were shown to activate this type of T cell response, and four out of these contain class I and II epitopes that, to our knowledge, are first described in this study. The remaining three contain sequences that had been previously demonstrated to induce CD8+ T cell response in Chagas’ disease patients, or bind HLA-A*02:01, but are, in this study, demonstrated to engage CD4+ T cells. We also assessed the degree of differentiation of activated T cells and looked into the HLA variants that might restrict the recognition of these peptides in the context of human T. cruzi infection. Key Points Novel T. cruzi T cell epitopes were identified by immunoinformatics and immunoassaying. Six class II and 1 class I epitopes activate T cells from chronic Chagas patients. Epitope-specific T cells have different memory phenotype across donors.
- 15 March 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 204 (6) , 1571-1581
In Silico Guided Discovery of Novel Class I and II Trypanosoma cruzi Epitopes Recognized by T Cells from Chagas’ Disease Patients
T cell–mediated immune response plays a crucial role in controlling Trypanosoma cruzi infection and parasite burden, but it is also involved in the clinical onset and progression of chronic Chagas’ disease. Therefore, the study of T cells is central to the understanding of the immune response against the parasite and its implications for the infected organism. The complexity of the parasite–host interactions hampers the identification and characterization of T cell–activating epitopes. We approached this issue by combining in silico and in vitro methods to interrogate patients’ T cells specificity. Fifty T. cruzi peptides predicted to bind a broad range of class I and II HLA molecules were selected for in vitro screening against PBMC samples from a cohort of chronic Chagas’ disease patients, using IFN-γ secretion as a readout. Seven of these peptides were shown to activate this type of T cell response, and four out of these contain class I and II epitopes that, to our knowledge, are first described in this study. The remaining three contain sequences that had been previously demonstrated to induce CD8+ T cell response in Chagas’ disease patients, or bind HLA-A*02:01, but are, in this study, demonstrated to engage CD4+ T cells. We also assessed the degree of differentiation of activated T cells and looked into the HLA variants that might restrict the recognition of these peptides in the context of human T. cruzi infection. Key Points Novel T. cruzi T cell epitopes were identified by immunoinformatics and immunoassaying. Six class II and 1 class I epitopes activate T cells from chronic Chagas patients. Epitope-specific T cells have different memory phenotype across donors.
- Open Access
- 23 August 2007
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 35 (17) , e113
Efficacy assessment of SNP sets for genome-wide disease association studies
The power of a genome-wide disease association study depends critically upon the properties of the marker set used, particularly the number and physical spacing of markers, and the level of inter-marker association due to linkage disequilibrium. Extending our previously devised theoretical framework for the entropy-based selection of genetic markers, we have developed a local measure of the efficacy of a marker set, relative to including a maximally polymorphic single nucleotide polymorphism (SNP) at the map position of interest. Using this quantitative criterion, we evaluated five currently available SNP sets, namely Affymetrix 100K and 500K, and Illumina 100K, 300K and 550K in the CEU, YRI and JPT + CHB HapMap populations. At 50% relative efficacy, the commercial marker sets cover between 19 and 68% of the human genome, depending upon the population under study. An optimal technology-independent 500K marker set constructed from HapMap for Caucasians, in contrast, would achieve 73% coverage at the same relative efficacy.
- 23 August 2007
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 35 (17) , e113
Open AccessEfficacy assessment of SNP sets for genome-wide disease association studies
The power of a genome-wide disease association study depends critically upon the properties of the marker set used, particularly the number and physical spacing of markers, and the level of inter-marker association due to linkage disequilibrium. Extending our previously devised theoretical framework for the entropy-based selection of genetic markers, we have developed a local measure of the efficacy of a marker set, relative to including a maximally polymorphic single nucleotide polymorphism (SNP) at the map position of interest. Using this quantitative criterion, we evaluated five currently available SNP sets, namely Affymetrix 100K and 500K, and Illumina 100K, 300K and 550K in the CEU, YRI and JPT + CHB HapMap populations. At 50% relative efficacy, the commercial marker sets cover between 19 and 68% of the human genome, depending upon the population under study. An optimal technology-independent 500K marker set constructed from HapMap for Caucasians, in contrast, would achieve 73% coverage at the same relative efficacy.